HIV-1 MN NO Fragment
Home > Catalog Peptides > HIV-1 MN NO Fragment

If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!

HIV-1 MN NO Fragment

Browse products name by alphabetical order:

ALL H
Cat. # Product Name Price
H09777 HIV - 1 MN #2048 Inquiry
H09695 HIV - 1 MN #2047 Inquiry
H09716 HIV - 1 MN #2037 Inquiry
H09863 HIV - 1 MN #2031 Inquiry
H09837 HIV - 1 MN #2030 Inquiry
H09820 HIV - 1 MN #2029 Inquiry
H09869 HIV - 1 MN #2027 Inquiry
H09728 HIV - 1 MN #2025 Inquiry
H09186 HIV - 1 MN #2024 Inquiry
H09040 HIV - 1 MN #2023 Inquiry
H09816 HIV - 1 MN #2022 Inquiry
H09813 HIV - 1 MN #2021 Inquiry
H09753 HIV - 1 MN #2019 Inquiry
H09782 HIV - 1 MN #2015 Inquiry
H09735 HIV - 1 MN #2014 Inquiry

HIV-1 MN isolate was taken from a pediatric AIDS patient located in the U.S. in 1984. Since MN strain is the most representative epidemic virus in the American population, scientists studied the infectivity of a series of serum samples from children infected with HIV and MN strain. The initial serum antibody titer analysis showed that MN neutralizing antibody was not related to age, sex, CD4 cell count, p24 antigen level, collection pathway, and CDC symptom grade. This viral strain exhibits the same cytopathic effects on H9 cells as HTLV-IIIB. Also infects human neoplastic CD4+ T cells including H9, CEM, U937, Molt 3, Hela CD4+ cells, and human peripheral blood lymphocytes.

Correlation of neutralizing antibody with clinical status.

HIV-l syncytium-inhibiting antibodies have been recently correlated with better clinical outcome in HIV-l e-infected children. This also supports the concept that the humoral immune response to HIV infection plays an important role in determining the course of disease progression. The MN strain is prevalent in the United States and has been used in these studies to maximize the observed possible neutralization activity. However, if autogenous isolates are used, the expected results cannot be determined. Higher neutralizing antibody titers and their correlation with protection may be obtained, as autologous will allow for higher reactivity of type-specific antibodies. On the other hand, the selection deviation caused by virus isolation hinders the ability of autologous virus isolates to accurately express the virus spectrum in vivo. Therefore, even if autologous separation is used, the results may not be accurately reflected in the body. In addition, when isolating autologous viruses, non-neutralizing or poorly neutralizing isolates can be obtained, whether as viruses that have not yet induced antibodies or as escape mutants. This immune-selective escape mutant has been confirmed in vitro and in vivo.

Conclusion

At present, the research of HIV vaccine is still in the exploratory stage, people do not know how to achieve a successful vaccine, all the clinical research is a “conceptual trial”, which is still far from the real vaccine development. More than 20 years of research, more than 100 clinical trials, have not achieved the expected results, the main reason is that there is no clear understanding of the immune protection mechanism of HIV infection. Therefore, strengthening the basic research of HIV infection and immunization, especially from the vaccine point of view, should be the focus of HIV vaccine research for a long time.

References
1. Guroff, M. R., Roilides, E., Muldoon, R., Venzon, D., Husson, R., Marshall, D., ... & Pizzo, P. A. (1993). Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. Journal of Infectious Diseases167(3), 538-546.
2. Sengupta, S., & Siliciano, R. F. (2018). Targeting the latent reservoir for HIV-1. Immunity48(5), 872-895.

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

Follow us on:

Copyright © 2008 - Creative Peptides. All rights reserved.

USA

Address: 45-16 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882

Fax: 1-631-614-7828

E-Mail:

Europe

Tel: 44-207-097-1828

E-Mail: